Related Experiment Video
Updated: Jul 4, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
19.9K
A case of diffuse large B-cell lymphoma with interstitial pneumonia
Ge Song1, Changxi Zhou1, Shuxia Wang1
1Department of Geriatrics, The Second Medical Center & National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
Cancer Pathogenesis and Therapy
|February 8, 2024
Summary
A diffuse large B-cell lymphoma patient developed interstitial pneumonia during R-CDOP chemotherapy. Prompt "full coverage" treatment led to complete recovery of lung function, allowing subsequent therapy continuation.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Standard treatment regimens for DLBCL include chemotherapy combinations like R-CDOP.
- Chemotherapy can be associated with various side effects, including pulmonary complications.
Observation:
- A 54-year-old female with DLBCL presented with enlarged lymph nodes.
- She received the rituximab, cyclophosphamide, doxorubicin liposomes, vincristine, and prednisone (R-CDOP) regimen.
- After the 4th cycle, the patient developed shortness of breath, indicative of interstitial pneumonia (IP).
Findings:
- Lung CT confirmed interstitial pneumonia (IP) as a complication of R-CDOP therapy.
- The IP completely resolved with comprehensive supportive treatment.
- The patient successfully completed further CDOP cycles and radiotherapy, with ongoing follow-up.
Implications:
- This case highlights the importance of monitoring for pulmonary toxicity during DLBCL treatment.
- Early recognition and management of chemotherapy-induced IP are crucial for patient outcomes.
- The successful resolution of IP allowed for the continuation of effective DLBCL treatment.
Related Concept Videos
01:31Pulmonary Tuberculosis III
327
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
327
01:28Pulmonary Tuberculosis II
237
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
237
01:26Pulmonary Tuberculosis IV
143
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
143